BACKGROUND: A nationwide mass screening for neuroblastoma (NBL) in 6-month-old infants (MS6M) was performed in Japan from 1985 to 2003. Favorable biological features were identified for most of the detected tumors; consequently, we began an observation program for selected screened patients in 1993. Here, we report the clinicopathological findings and present status of patients enrolled in our observation program, with the goal of evaluating its usefulness. PROCEDURE: Between 1993 and 2003, 53 of 101 patients with NBL detected by MS6M were enrolled. The patients were divided into four groups according to changes in urinary VMA and HVA levels and tumor size. RESULTS: Urinary VMA and HVA levels decreased in 39 of 53 patients. In 17 of these 39 patients, the tumor became undetectable (Group A); in 22 patients the tumor was detectable (Group B). In seven patients, tumor marker levels varied, and tumor volume gradually increased (Group C). In six patients, tumor marker levels and tumor volume increased in the short term (Group D). One patient had multiple tumors (1M according to International Neuroblastoma Staging System). All tumors in Groups C and D, four tumors in Group B, and one tumor in the 1M patient were removed. No unfavorable biologic factors were noted in any excised tumor. CONCLUSIONS: The observation program of the present study, one of the largest series for MS6M, confirmed that over 70% of patients who fulfilled the criteria could be observed without surgery.
BACKGROUND: A nationwide mass screening for neuroblastoma (NBL) in 6-month-old infants (MS6M) was performed in Japan from 1985 to 2003. Favorable biological features were identified for most of the detected tumors; consequently, we began an observation program for selected screened patients in 1993. Here, we report the clinicopathological findings and present status of patients enrolled in our observation program, with the goal of evaluating its usefulness. PROCEDURE: Between 1993 and 2003, 53 of 101 patients with NBL detected by MS6M were enrolled. The patients were divided into four groups according to changes in urinary VMA and HVA levels and tumor size. RESULTS: Urinary VMA and HVA levels decreased in 39 of 53 patients. In 17 of these 39 patients, the tumor became undetectable (Group A); in 22 patients the tumor was detectable (Group B). In seven patients, tumor marker levels varied, and tumor volume gradually increased (Group C). In six patients, tumor marker levels and tumor volume increased in the short term (Group D). One patient had multiple tumors (1M according to International Neuroblastoma Staging System). All tumors in Groups C and D, four tumors in Group B, and one tumor in the 1M patient were removed. No unfavorable biologic factors were noted in any excised tumor. CONCLUSIONS: The observation program of the present study, one of the largest series for MS6M, confirmed that over 70% of patients who fulfilled the criteria could be observed without surgery.
Authors: Kieuhoa T Vo; Katherine K Matthay; John Neuhaus; Wendy B London; Barbara Hero; Peter F Ambros; Akira Nakagawara; Doug Miniati; Kate Wheeler; Andrew D J Pearson; Susan L Cohn; Steven G DuBois Journal: J Clin Oncol Date: 2014-08-25 Impact factor: 44.544
Authors: Pamela M Marcus; Philip C Prorok; Anthony B Miller; Emily J DeVoto; Barnett S Kramer Journal: J Natl Cancer Inst Date: 2015-02-06 Impact factor: 13.506
Authors: Suzanne P MacFarland; Sogol Mostoufi-Moab; Kristin Zelley; Peter A Mattei; Lisa J States; Tricia R Bhatti; Kelly A Duffy; Garrett M Brodeur; Jennifer M Kalish Journal: Pediatr Blood Cancer Date: 2017-01-09 Impact factor: 3.167
Authors: Eric R Gamazon; Navin Pinto; Anuar Konkashbaev; Hae Kyung Im; Sharon J Diskin; Wendy B London; John M Maris; M Eileen Dolan; Nancy J Cox; Susan L Cohn Journal: J Natl Cancer Inst Date: 2012-12-14 Impact factor: 13.506
Authors: Jed G Nuchtern; Wendy B London; Carol E Barnewolt; Arlene Naranjo; Patrick W McGrady; James D Geiger; Lisa Diller; Mary Lou Schmidt; John M Maris; Susan L Cohn; Robert C Shamberger Journal: Ann Surg Date: 2012-10 Impact factor: 12.969
Authors: Ana S Guerreiro Stucklin; Scott Ryall; Kohei Fukuoka; Michal Zapotocky; Alvaro Lassaletta; Christopher Li; Taylor Bridge; Byungjin Kim; Anthony Arnoldo; Paul E Kowalski; Yvonne Zhong; Monique Johnson; Claire Li; Arun K Ramani; Robert Siddaway; Liana Figueiredo Nobre; Pasqualino de Antonellis; Christopher Dunham; Sylvia Cheng; Daniel R Boué; Jonathan L Finlay; Scott L Coven; Inmaculada de Prada; Marta Perez-Somarriba; Claudia C Faria; Michael A Grotzer; Elisabeth Rushing; David Sumerauer; Josef Zamecnik; Lenka Krskova; Miguel Garcia Ariza; Ofelia Cruz; Andres Morales La Madrid; Palma Solano; Keita Terashima; Yoshiko Nakano; Koichi Ichimura; Motoo Nagane; Hiroaki Sakamoto; Maria Joao Gil-da-Costa; Roberto Silva; Donna L Johnston; Jean Michaud; Bev Wilson; Frank K H van Landeghem; Angelica Oviedo; P Daniel McNeely; Bruce Crooks; Iris Fried; Nataliya Zhukova; Jordan R Hansford; Amulya Nageswararao; Livia Garzia; Mary Shago; Michael Brudno; Meredith S Irwin; Ute Bartels; Vijay Ramaswamy; Eric Bouffet; Michael D Taylor; Uri Tabori; Cynthia Hawkins Journal: Nat Commun Date: 2019-09-25 Impact factor: 14.919